Feedback PLC Appointment of Non-Executive Chairman (9078Z)
June 01 2016 - 6:30AM
UK Regulatory
TIDMFDBK
RNS Number : 9078Z
Feedback PLC
01 June 2016
1 June 2016
Feedback plc
("Feedback" or the "Company")
Appointment of Non-Executive Chairman
Feedback plc (AIM: FDBK), the medical imaging software company,
is pleased to announce the appointment of Dr Alastair Riddell as
Non-Executive Chairman with immediate effect. Dr Riddell succeeds
Tom Charlton, who becomes Deputy Chairman and who will step down
from the board at the conclusion of the AGM which is likely to be
held in November 2016.
Dr Riddell, 67, has over 30 years' experience in the
pharmaceutical, life science and biotech industries, with 18 years
as a main board director. After 10 years directing phases 1-4
clinical trials of antibiotics, oncology and intensive care
products for companies including Lederle (now Pfizer) and Centocor
(now J&J), he spent five years managing sales and marketing for
oncology and imaging products for Amersham International (now GE
Healthcare). This led to 12 years as CEO for three UK biotech
companies, Pharmagene, Paradigm Therapeutics and Stem Cell
Sciences; in these roles he was the principal involved in an IPO on
UK's main list, trade sales to international companies in Japan and
the USA and significant fund raising rounds. He has been Chairman
of Silence Therapeutics (AIM listed) and Chairman of Definigen Ltd,
a private Cambridge University spinout. He is currently on the
Board of three biotechnology companies; AzurRx Biotherapeutics, a
private New York based drug development company; Cristal
Therapeutics, a Netherlands based company specialising in
nanoparticle medicines; and Skyline Vet Pharma, a US based private
company repurposing human drugs for use in companion animals. He is
also Chairman of the SWAHSN (South West Academic Health Science
Network), which seeks to improve and sustain the healthcare
provision in the south-west of England by linking innovation from
industry, academia and the NHS.
Dr Alastair Riddell commented: "I am very pleased to be joining
Feedback as it positions itself for growth in the critical market
of diagnostic imaging. Its early product in image software analysis
is gaining traction in assisting in the interpretation of cancer
deposits in lungs. The technology lends itself to other disease
areas and seeks to be a seamless addition to existing image
analysis procedures that will provide increased confidence in
diagnostic accuracy. I am looking forward to helping the Company
develop its infrastructure and resources to maximise its
potential."
Tom Charlton, said: "I recently informed the Board that I wished
to devote more time to my other investment activities and I
intended to step down from the Board at the time of the AGM later
this year. As Deputy Chairman, I will retain responsibility for
financial matters including the preparation of the annual report
and accounts for the year ended May 2016. Alastair has considerable
experience as a biotech entrepreneur and will provide knowledgeable
leadership to Feedback as we seek to commercialise TexRAD and grow
its revenues. His appointment has my full support as well as that
of the Board and I very much look forward to working with him."
Tom Charlton has made a conditional gift of 5,000,000 ordinary
shares in Feedback plc to Dr Alastair Riddell. The gift is
conditional on both Dr Riddell's election as a director at the 2016
AGM and it also being an open period for dealing under the AIM
rules.
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for
Companies the following information is disclosed in respect to Dr
Alastair James Riddell:
Current Appointments Former Appointments
AJR & Associates LTD Asset Realisation Company
Limited
AzurRX Bio Pharma Inc Definigen Limited
Cristal Therapeutics PCT Shareholders Limited
Skyline Vet Pharma Inc Silence Therapeutics
plc
South West Peninsula AHSN
Limited
There is no other information regarding Dr Riddell required to
be disclosed under the AIM Rules.
For further information, contact:
Feedback plc Tel: 01954 718072
Trevor Brown / Tom Charlton /
Balaji Ganeshan/ Mike Hayball
Allenby Capital Limited (Nominated Tel: 020 3328
Adviser and Joint Broker) 5656
Simon Clements / James Thomas
Peterhouse Corporate Finance Ltd Tel: 020 7469
(Joint Broker) 0936
Lucy Williams / Duncan Vasey
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAEAFKFEAKKEFF
(END) Dow Jones Newswires
June 01, 2016 07:30 ET (11:30 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
From Apr 2024 to May 2024
Feedback (LSE:FDBK)
Historical Stock Chart
From May 2023 to May 2024